John M. Pagel, MD, PhD

Articles

Minimal Residual Disease Testing for Patients with Chronic Lymphocytic Leukemia

August 25th 2021

Adaptive Biotechnologies OncLive Sponsored Content Q&A

Dr. Pagel on Determining Treatment Based on Genetic Risk in Double- and Triple-Hit Lymphoma

September 29th 2020

John M. Pagel, MD, PhD, discusses the utility of rituximab with etoposide, doxorubicin, cyclophosphamide, vincristine, and prednisone in double- and triple-hit lymphoma.

Dr. Pagel on the Utility of CAR T-Cell Therapy in Relapsed/Refractory DLBCL

September 22nd 2020

John M. Pagel, MD, PhD, discusses the utility of CAR T-cell therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.

Dr. Pagel on the Evolution of Treatment in DLBCL

September 16th 2020

John M. Pagel, MD, PhD, discusses the evolution of treatment in diffuse large B-cell lymphoma.

Dr. Pagel on Challenges With ASCT in Relapsed/Refractory DLBCL

August 18th 2020

John M. Pagel, MD, PhD, discusses challenges with autologous stem cell transplant in relapsed/refractory diffuse large B-cell lymphoma.

Dr. Pagel on the Importance of Screening for Double- and Triple-Hit DLBCL

August 13th 2020

John M. Pagel, MD, PhD, discusses the importance of screening patients for double-hit and triple-hit diffuse large B-cell lymphoma.

Dr. Pagel on the Implications of Polatuzumab Vedotin Approval in DLBCL

May 14th 2020

John M. Pagel, MD, PhD, discusses the implications of the FDA approval of polatuzumab vedotin in diffuse large B-cell lymphoma.

Dr. Pagel on the Implications of Polatuzumab Vedotin Approval in DLBCL

May 13th 2020

John M. Pagel, MD, PhD, discusses the implications of the FDA approval of polatuzumab vedotin in diffuse large B-cell lymphoma.

Dr. Pagel on the Shift Toward Precision Medicine in Large Cell Lymphoma

May 7th 2020

John M. Pagel, MD, PhD, chief of the Hematologic Malignancies Program, and director, Hematopoietic Cell Transplantation Program, at Swedish Cancer Institute, discusses the shift toward precision medicine in large cell lymphoma.

Dr. Pagel on Ongoing Research With BTK Inhibitors in CLL

May 6th 2020

John M. Pagel, MD, PhD, chief of the Hematologic Malignancies Program, and director, Hematopoietic Cell Transplantation Program, at Swedish Cancer Institute, discusses ongoing research with BTK inhibitors in chronic lymphocytic leukemia (CLL).

Dr. Pagel on Time-Limited Therapy in CLL

March 4th 2020

John M. Pagel, MD, PhD, discusses time-limited therapy in chronic lymphocytic leukemia.

Dr. Pagel on the ELEVATE-TN Trial in CLL

January 21st 2020

John M. Pagel, MD, PhD, discusses the phase III ELEVATE-TN trial in chronic lymphocytic leukemia.

Dr. Pagel on Biosimilars and Cost Consciousness in Oncology

December 13th 2019

John M. Pagel, MD, PhD, discusses the use of biosimilars in oncology and the importance of cost consciousness.